Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Hu19-CD828Z T cells |
Trade Name | |
Synonyms | HuCD19 anti-CD19 CAR-T cells |
Drug Descriptions |
Hu19-CD828Z T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19, and contains CD8alpha hinge and transmembrane domains, a CD28 costimulatory domain, and a CD3 activation domain, which may induce antitumor activity (PMID: 31959992). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Hu19-CD828Z T cells | Hu19-CD828Z T cells | 0 | 0 |
Hu19-CD828Z T cells + Rituximab | Hu19-CD828Z T cells Rituximab | 0 | 1 |